Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

NHLBI

Drug and asset intelligence for NHLBI with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 4
Stage: Development stage unavailable

Sponsor company

neurology pharmaceutical companies →

Recent signals(5)

ClinicalJuly 30, 2026

NHLBI Launches MAP-HEART Study to Analyze Heart Failure Phenotypes

The MAP-HEART study aims to collect and analyze biological samples from heart failure patients to identify factors affecting heart function.

ClinicalJuly 4, 2026

Study on Psoriasis and Cardiometabolic Disease Relationship Launched by NHLBI

The NHLBI has initiated a study to explore the relationship between psoriasis and cardiometabolic diseases.

ClinicalJuly 4, 2026

NHLBI Study on Dyslipidemias Evaluates Lipid Disorders and Their Impact

The NHLBI is conducting a study to evaluate individuals with dyslipidemias, focusing on lipid levels and related health risks.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(4)

Topline Data

— NHLBI

July 4, 2026 · N/A

Topline Data

— NHLBI

July 4, 2026 · N/A

Topline Data

— NHLBI

June 29, 2026 · N/A

Topline Data

— NHLBI

June 29, 2026 · N/A

Indications

Therapeutic areas

Cardiology · Dyslipidemia →

Cardiology · Imaging →

Dermatology →

Dermatology · Psoriasis →

Dyslipidemia →

Heart Failure →

Neurology · CADASIL →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

ClinicalJune 29, 2026

NHLBI Launches Study on 18F-FAPI-74 PET/CT Imaging for Early Detection of Fibrosis

The NHLBI is conducting a trial to evaluate the efficacy of 18F-FAPI-74 PET/CT imaging in detecting early-stage fibrosis in heart and lung diseases.

ClinicalJune 29, 2026

Natural History Study of CADASIL Launched by NHLBI to Monitor Disease Progression

The NHLBI has initiated a long-term study to monitor the progression of CADASIL in affected individuals and healthy volunteers.